Rare serious allergic reactions including angioneurotic oedema & anaphylaxis (rarely fatal). Precipitated ergotism in concomitant use w/ ergotamine derivatives; patients w/ increased risk for prolonged cardiac repolarisation; congenital or documented acquired QT prolongation; currently treatment w/ other active substances known to prolong QT interval, eg antiarrhythmics class IA & III, cisapride & terfenadine; electrolyte disturbance, particularly hypokalemia & hypomagnesaemia; bradycardia, cardiac arrhythmia or severe cardiac insufficiency. Clostridium difficile
associated diarrhoea may occur. Exacerbations of myasthenia gravis symptoms & new onset of myasthenia gravis. Observe for signs & superinfection w/ non-susceptible organisms including fungi. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption. May affect ability to drive or operate machinery. 33% increased systemic exposure in patients w/ severe renal impairment (GFR <10 mL/min). Patients w/ significant hepatic disease; fulminant hepatitis potentially leading to life-threatening hepatic failure; perform hepatic function tests/investigations w/ occurrence of signs & symptoms eg, rapid asthenia development associated w/ jaundice, dark urine, bleeding tendency or hepatic encephalopathy. Pregnancy & lactation (discontinue breastfeeding during treatment until 2 days after discontinuation of treatment).